Drugs / azficel-T
azficel-T
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00655889 | Jan 2006 → Apr 2008 | — | Castle Creek Biosciences, LLC. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00642642 | Nov 2007 → Mar 2009 | acne | Castle Creek Biosciences, LLC. | Completed | Met primary |
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT00655356 | Nov 2006 → Jul 2008 | — | Castle Creek Biosciences, LLC. | Completed | Met primary |
| Phase 3 | NCT00649428 | Oct 2006 → Jul 2008 | — | Castle Creek Biosciences, LLC. | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | azficel-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00649428 ↗ |
| Known as | Autologous cultured fibroblasts | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107865 ↗ |
| Known as | Autologous Human Fibroblasts | “Autologous Human Fibroblasts (azficel-T)” NCT00642642 ↗ |
| Known as | Laviv | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107865 ↗ |
| Modality | Cell therapy | “Autologous Human Fibroblasts (azficel-T)” NCT00642642 ↗ |
| Route | Other | “Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face.” NCT00655356 ↗ |